Log in to your Inderes Free account to see all free content on this page.
Cinclus Pharma
17.7
SEK
-3.56 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-3.56%
-16.37%
-17.21%
-23.06%
-46.23%
-
-
-
-45.71%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
838.84M SEK
Turnover
939.02K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
20.2.
2025
Annual report '24
19.5.
2025
Interim report Q1'25
22.5.
2025
General meeting '25
ShowingAll content types
Number of shares and votes in Cinclus Pharma
Linaprazan glurate receives marketing approval in China
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio